2400 related articles for article (PubMed ID: 30388455)
1. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Jerby-Arnon L; Shah P; Cuoco MS; Rodman C; Su MJ; Melms JC; Leeson R; Kanodia A; Mei S; Lin JR; Wang S; Rabasha B; Liu D; Zhang G; Margolais C; Ashenberg O; Ott PA; Buchbinder EI; Haq R; Hodi FS; Boland GM; Sullivan RJ; Frederick DT; Miao B; Moll T; Flaherty KT; Herlyn M; Jenkins RW; Thummalapalli R; Kowalczyk MS; Cañadas I; Schilling B; Cartwright ANR; Luoma AM; Malu S; Hwu P; Bernatchez C; Forget MA; Barbie DA; Shalek AK; Tirosh I; Sorger PK; Wucherpfennig K; Van Allen EM; Schadendorf D; Johnson BE; Rotem A; Rozenblatt-Rosen O; Garraway LA; Yoon CH; Izar B; Regev A
Cell; 2018 Nov; 175(4):984-997.e24. PubMed ID: 30388455
[TBL] [Abstract][Full Text] [Related]
2. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
3. Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.
Lelliott EJ; Mangiola S; Ramsbottom KM; Zethoven M; Lim L; Lau PKH; Oliver AJ; Martelotto LG; Kirby L; Martin C; Patel RP; Slater A; Cullinane C; Papenfuss AT; Haynes NM; McArthur GA; Oliaro J; Sheppard KE
Cancer Immunol Res; 2021 Feb; 9(2):136-146. PubMed ID: 33303574
[TBL] [Abstract][Full Text] [Related]
4. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
5. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Deng J; Wang ES; Jenkins RW; Li S; Dries R; Yates K; Chhabra S; Huang W; Liu H; Aref AR; Ivanova E; Paweletz CP; Bowden M; Zhou CW; Herter-Sprie GS; Sorrentino JA; Bisi JE; Lizotte PH; Merlino AA; Quinn MM; Bufe LE; Yang A; Zhang Y; Zhang H; Gao P; Chen T; Cavanaugh ME; Rode AJ; Haines E; Roberts PJ; Strum JC; Richards WG; Lorch JH; Parangi S; Gunda V; Boland GM; Bueno R; Palakurthi S; Freeman GJ; Ritz J; Haining WN; Sharpless NE; Arthanari H; Shapiro GI; Barbie DA; Gray NS; Wong KK
Cancer Discov; 2018 Feb; 8(2):216-233. PubMed ID: 29101163
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 Inhibitors in Melanoma: A Comprehensive Review.
Garutti M; Targato G; Buriolla S; Palmero L; Minisini AM; Puglisi F
Cells; 2021 May; 10(6):. PubMed ID: 34071228
[TBL] [Abstract][Full Text] [Related]
8. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.
Lelliott EJ; Kong IY; Zethoven M; Ramsbottom KM; Martelotto LG; Meyran D; Zhu JJ; Costacurta M; Kirby L; Sandow JJ; Lim L; Dominguez PM; Todorovski I; Haynes NM; Beavis PA; Neeson PJ; Hawkins ED; McArthur GA; Parish IA; Johnstone RW; Oliaro J; Sheppard KE; Kearney CJ; Vervoort SJ
Cancer Discov; 2021 Oct; 11(10):2582-2601. PubMed ID: 33990344
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
11. A T-rojan horse strategy for cancer immunotherapy.
Rafie C; Pillai A
Sci Immunol; 2021 May; 6(59):. PubMed ID: 33963062
[TBL] [Abstract][Full Text] [Related]
12. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
13. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer.
Wang Q; Guldner IH; Golomb SM; Sun L; Harris JA; Lu X; Zhang S
Nat Commun; 2019 Aug; 10(1):3817. PubMed ID: 31444334
[TBL] [Abstract][Full Text] [Related]
14. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Phadke MS; Chen Z; Li J; Mohamed E; Davies MA; Smalley I; Duckett DR; Palve V; Czerniecki BJ; Forsyth PA; Noyes D; Adeegbe DO; Eroglu Z; Nguyen KT; Tsai KY; Rix U; Burd CE; Chen YA; Rodriguez PC; Smalley KSM
Cancer Immunol Res; 2021 May; 9(5):554-567. PubMed ID: 33653716
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor.
Zaemes J; Alzeer A; Villa K; Atkins M
Immunotherapy; 2020 Aug; 12(12):861-867. PubMed ID: 32640856
[No Abstract] [Full Text] [Related]
18. Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation.
Heckler M; Ali LR; Clancy-Thompson E; Qiang L; Ventre KS; Lenehan P; Roehle K; Luoma A; Boelaars K; Peters V; McCreary J; Boschert T; Wang ES; Suo S; Marangoni F; Mempel TR; Long HW; Wucherpfennig KW; Dougan M; Gray NS; Yuan GC; Goel S; Tolaney SM; Dougan SK
Cancer Discov; 2021 Oct; 11(10):2564-2581. PubMed ID: 33941591
[TBL] [Abstract][Full Text] [Related]
19. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J; Vredevoogd DW; Krijgsman O; Ligtenberg MA; Blankenstein S; de Bruijn B; Frederick DT; Kenski JCN; Parren M; Brüggemann M; Madu MF; Rozeman EA; Song JY; Horlings HM; Blank CU; van Akkooi ACJ; Flaherty KT; Boland GM; Peeper DS
Nat Commun; 2020 Aug; 11(1):3946. PubMed ID: 32770055
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]